Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early access and safety study of cabazitaxel in metastatic hormone-refractory prostate cancer after docetaxel
2010-021128-92Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2010
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cabazitaxel in prostate cancer (PCa), sponsored by Sanofi. Started Oct 2010; status: completed.
02
Drugs
cabazitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-021128-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021128-92.